Product Description
Autologous CAR-T for T-ALL/AML. (Sourced from: http://www.gzbiogene.com/english.php/Product/index)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Autologous CAR-T
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Guangzhou Bio-gene Technology Co., Ltd
Company Location: Asia Pacific
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Acute Myeloid Leukemia|Acute Lymphoid Leukemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|